clonidine has been researched along with Coronary Disease in 41 studies
Clonidine: An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION.
clonidine (amino form) : A clonidine that is 4,5-dihydro-1H-imidazol-2-amine in which one of the amino hydrogens is replaced by a 2,6-dichlorophenyl group.
Coronary Disease: An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To access the clinical effect of clonidine on reduction of myocardial ischemia events in patients with history of coronary artery disease undergoing noncardiac surgeries." | 9.10 | Oral clonidine reduces myocardial ischemia in patients with coronary artery disease undergoing noncardiac surgery. ( Chan, KH; Chow, LH; Chu, CC; Tsai, SK; Tsao, CM; Tsou, MY; Yin, YC, 2002) |
| "Imipramine improved the symptoms of patients with chest pain and normal coronary angiograms, possibly through a visceral analgesic effect." | 9.07 | Imipramine in patients with chest pain despite normal coronary angiograms. ( Black, BC; Cannon, RO; Geraci, MF; Gracely, RH; Mincemoyer, R; Quyyumi, AA; Smith, WB; Stine, AM; Uhde, TW; Waclawiw, MA, 1994) |
| "11 coronary patients, 8 with mild hypertension, were treated with clonidine, at a dose of 75 micrograms b." | 7.66 | The therapeutic value of clonidine in patients with coronary heart disease. ( Amrein, R; Chu, D; Cocco, G; Haeusler, G; Padovan, GC; Strozzi, C, 1979) |
| "To access the clinical effect of clonidine on reduction of myocardial ischemia events in patients with history of coronary artery disease undergoing noncardiac surgeries." | 5.10 | Oral clonidine reduces myocardial ischemia in patients with coronary artery disease undergoing noncardiac surgery. ( Chan, KH; Chow, LH; Chu, CC; Tsai, SK; Tsao, CM; Tsou, MY; Yin, YC, 2002) |
| " Clonidine reduced enflurane requirements, intraoperative tachycardia, and myocardial ischemia (1/28 clonidine patients vs 5/24 placebo, P = 0." | 5.07 | Premedication with oral and transdermal clonidine provides safe and efficacious postoperative sympatholysis. ( Busse, JR; Drijvers, G; Ellis, JE; Foss, JF; Laff, SP; Mantha, S; McKinsey, JF; Pedlow, S; Shah, M; Sorrentino, MJ, 1994) |
| "Imipramine improved the symptoms of patients with chest pain and normal coronary angiograms, possibly through a visceral analgesic effect." | 5.07 | Imipramine in patients with chest pain despite normal coronary angiograms. ( Black, BC; Cannon, RO; Geraci, MF; Gracely, RH; Mincemoyer, R; Quyyumi, AA; Smith, WB; Stine, AM; Uhde, TW; Waclawiw, MA, 1994) |
| "Automatic arrhythmias induced by alpha 1-adrenergic stimulation during simulated ischemia may be attributed to a specific alpha 1-adrenergic receptor subtype that is blocked by WB 4101." | 3.68 | Abnormal automatic rhythms in ischemic Purkinje fibers are modulated by a specific alpha 1-adrenergic receptor subtype. ( Anyukhovsky, EP; Rosen, MR, 1991) |
| "Alinidine is a bradycardic agent, which appears to be of potential value in the therapy of coronary heart disease." | 3.67 | Acute haemodynamic effects of a specific bradycardic agent in patients with coronary heart disease and impaired left ventricular function. ( Kreuzer, H; Wiegand, V, 1987) |
| "11 coronary patients, 8 with mild hypertension, were treated with clonidine, at a dose of 75 micrograms b." | 3.66 | The therapeutic value of clonidine in patients with coronary heart disease. ( Amrein, R; Chu, D; Cocco, G; Haeusler, G; Padovan, GC; Strozzi, C, 1979) |
| "Midazolam was associated with a greater sedative and cardiovascular effect, whereas for diazepam these effects were less intense." | 2.73 | Sedative and cardiovascular effects of midazolam and diazepam alone or combined with clonidine in patients undergoing hemodynamic studies for suspected coronary artery disease. ( Carvalho, HG; Modolo, NS; Nascimento, Jdos S; Santos, KP; Silva, RC, 2007) |
| "Treatment with clonidine markedly suppressed norepinephrine levels during exercise (matched peak exercise workload: control, 2137 +/- 187 versus clonidine, 1430 +/- 161 pg/mL), increased leg blood flow (control, 1." | 2.68 | Effect of sympathoinhibition on exercise performance in patients with heart failure. ( Chomsky, DB; Lang, CC; Rayos, GH; Wilson, JR; Wood, AJ, 1997) |
| "Clonidine was administered during surgery, and beta-blockers were titrated after surgery to achieve heart rates less than 80 bpm." | 1.31 | The impact of a cardioprotective protocol on the incidence of cardiac complications after aortic abdominal surgery. ( Bednarkiewicz, M; Chevalley, C; Khatchatourian, G; Licker, M; Schweizer, A; Tassaux, D, 2002) |
| "Clonidine is a valuable adjunct for conscious sedation and can be used safely for sympathicolysis, even in patients with aortic stenosis." | 1.31 | Difficult airway management in a patient with severe aortic stenosis, coronary artery disease, and heart failure. ( Kulka, PJ; Tryba, M; Zenz, M, 2002) |
| "Alinidine is a new bradycardic agent that interferes with ion channels and the if pacemaker current." | 1.28 | Effects of alinidine on metabolic response to high-demand myocardial ischemia. ( Caucheteux, D; Gurné, O; Hanet, C; Hue, L; Maldague, P; Pouleur, H; Rousseau, MF, 1989) |
| "Propranolol was infused into the bypass tube to exclude the metabolic effects of norepinephrine." | 1.28 | Beneficial effects of alpha 2-adrenoceptor activity on ischemic myocardium during coronary hypoperfusion in dogs. ( Gotoh, K; Hori, M; Inoue, M; Iwakura, K; Kamada, T; Kitabatake, A; Kitakaze, M; Sato, H, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 27 (65.85) | 18.7374 |
| 1990's | 9 (21.95) | 18.2507 |
| 2000's | 5 (12.20) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Licker, M | 1 |
| Khatchatourian, G | 1 |
| Schweizer, A | 1 |
| Bednarkiewicz, M | 1 |
| Tassaux, D | 1 |
| Chevalley, C | 1 |
| Yin, YC | 1 |
| Chow, LH | 1 |
| Tsao, CM | 1 |
| Chu, CC | 1 |
| Tsou, MY | 1 |
| Chan, KH | 1 |
| Tsai, SK | 1 |
| Nascimento, Jdos S | 1 |
| Modolo, NS | 1 |
| Silva, RC | 1 |
| Santos, KP | 1 |
| Carvalho, HG | 1 |
| Menard, J | 1 |
| Michel, JB | 1 |
| Dussaule, JC | 1 |
| Alhenc-Gelas, F | 1 |
| Corvol, P | 1 |
| Wilber, JA | 1 |
| Ram, CV | 2 |
| Brandt, D | 1 |
| Schurmans, J | 1 |
| Piessens, J | 1 |
| Kesteloot, H | 1 |
| De Geest, H | 1 |
| Thormann, J | 1 |
| Neuss, H | 1 |
| Schlepper, M | 2 |
| Mitrovic, V | 1 |
| Löllgen, H | 1 |
| Just, H | 1 |
| Wollschläger, H | 1 |
| Kersting, F | 1 |
| Ellis, JE | 1 |
| Drijvers, G | 1 |
| Pedlow, S | 1 |
| Laff, SP | 1 |
| Sorrentino, MJ | 1 |
| Foss, JF | 1 |
| Shah, M | 1 |
| Busse, JR | 1 |
| Mantha, S | 1 |
| McKinsey, JF | 1 |
| Cannon, RO | 1 |
| Quyyumi, AA | 1 |
| Mincemoyer, R | 1 |
| Stine, AM | 1 |
| Gracely, RH | 1 |
| Smith, WB | 1 |
| Geraci, MF | 1 |
| Black, BC | 1 |
| Uhde, TW | 1 |
| Waclawiw, MA | 1 |
| Stühmeier, KD | 1 |
| Mainzer, B | 1 |
| Cierpka, J | 1 |
| Sandmann, W | 1 |
| Tarnow, J | 1 |
| Nishikawa, T | 1 |
| Lang, CC | 1 |
| Rayos, GH | 1 |
| Chomsky, DB | 1 |
| Wood, AJ | 1 |
| Wilson, JR | 1 |
| Arnar, DO | 1 |
| Xing, D | 1 |
| Lee, H | 1 |
| Martins, JB | 1 |
| Kulka, PJ | 1 |
| Tryba, M | 1 |
| Zenz, M | 1 |
| Cocco, G | 1 |
| Strozzi, C | 1 |
| Haeusler, G | 1 |
| Chu, D | 1 |
| Amrein, R | 1 |
| Padovan, GC | 1 |
| Piancone, RM | 1 |
| Mucedola, LB | 1 |
| Antonucci, G | 1 |
| Lipartiti, P | 1 |
| Marangi, M | 1 |
| Rispoli, M | 1 |
| Rotenberg, FA | 1 |
| Verrier, RL | 1 |
| Lown, B | 1 |
| Sole, MJ | 1 |
| Anyukhovsky, EP | 1 |
| Rosen, MR | 1 |
| Julius, S | 1 |
| Schad, H | 1 |
| Heimisch, W | 1 |
| Haas, F | 1 |
| Mendler, N | 1 |
| Ditter, H | 1 |
| Müller, KD | 1 |
| Bahavar, H | 1 |
| Heusch, G | 1 |
| Schipke, J | 1 |
| Thämer, V | 1 |
| Hanet, C | 1 |
| Pouleur, H | 1 |
| Hue, L | 1 |
| Caucheteux, D | 1 |
| Gurné, O | 1 |
| Maldague, P | 1 |
| Rousseau, MF | 1 |
| Galassi, AR | 1 |
| Kaski, JC | 1 |
| Pupita, G | 1 |
| Vejar, M | 1 |
| Crea, F | 1 |
| Maseri, A | 1 |
| Kitakaze, M | 1 |
| Hori, M | 1 |
| Gotoh, K | 1 |
| Sato, H | 1 |
| Iwakura, K | 1 |
| Kitabatake, A | 1 |
| Inoue, M | 1 |
| Kamada, T | 1 |
| Basile, V | 1 |
| Marino, A | 1 |
| Drímal, J | 1 |
| Magna, D | 1 |
| Knezl, V | 1 |
| Sotnikova, R | 1 |
| Harron, DW | 2 |
| Shanks, RG | 1 |
| Motz, W | 1 |
| Strauer, BE | 1 |
| Stieglitz, P | 1 |
| Quintin, L | 1 |
| Ghignone, M | 1 |
| Carlsson, L | 1 |
| Abrahamsson, T | 1 |
| Wiegand, V | 1 |
| Kreuzer, H | 1 |
| Raberger, G | 1 |
| Krumpl, G | 1 |
| Schneider, W | 1 |
| Mayer, N | 1 |
| Meese, RB | 1 |
| Brezina, M | 1 |
| Lillie, C | 1 |
| Kobinger, W | 1 |
| Jaski, BE | 1 |
| Serruys, PW | 1 |
| Raftos, J | 1 |
| Bauer, GE | 1 |
| Lewis, RG | 1 |
| Stokes, GS | 1 |
| Mitchell, AS | 1 |
| Young, AA | 1 |
| Maclachlan, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pain Measurement in Healthy Volunteers[NCT00001597] | 40 participants | Observational | 1997-03-31 | Completed | |||
| Psychophysiological Interactions in Non-Cardiac Chest Pain[NCT00005575] | Phase 3 | 0 participants | Interventional | 1999-01-31 | Completed | ||
| WISE Ancillary Study Data Analyses: Efficacy of Hormone Replacement on Myocardial Ischemia in Postmenopausal Women With Normal/Minimal Coronary Artery Disease: Data Analysis[NCT00600106] | 37 participants (Actual) | Interventional | 1999-12-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Endothelial dysfunction refers to altered vasoactive, anticoagulant, and anti-inflammatory properties of endothelium, and dysregulated vascular growth remodeling that results from a loss of nitric oxide (NO) bioactivity in the endothelium. Brachial Artery Reactivity Testing (BART), high-frequency ultrasonographic imaging of the brachial artery, evaluates flow-mediated vasodilation (FMD), an endothelium-dependent function. The technique provokes the release of nitric oxide, resulting in vasodilation that can be quantitated as an index of endothelial dysfunction.~Flow-mediated vasodilation is typically expressed as the change in post-stimulus diameter as a percentage of the baseline diameter [diameter after cuff deflation - baseline diameter / baseline diameter) x 100]." (NCT00600106)
Timeframe: Baseline
| Intervention | percentage of pre-stimulus diameter (Mean) |
|---|---|
| Hormone Replacement Therapy | 8.2 |
| Placebo | 8.8 |
"Endothelial dysfunction refers to altered vasoactive, anticoagulant, and anti-inflammatory properties of endothelium, and dysregulated vascular growth remodeling that results from a loss of nitric oxide (NO) bioactivity in the endothelium. Brachial Artery Reactivity Testing (BART), high-frequency ultrasonographic imaging of the brachial artery, evaluates flow-mediated vasodilation (FMD), an endothelium-dependent function. The technique provokes the release of nitric oxide, resulting in vasodilation that can be quantitated as an index of vasomotor function.~Flow-mediated vasodilation is typically expressed as the change in post-stimulus diameter as a percentage of the baseline diameter [diameter after cuff deflation - baseline diameter / baseline diameter) x 100]." (NCT00600106)
Timeframe: 12 weeks
| Intervention | percentage of pre-stimulus diameter (Mean) |
|---|---|
| Hormone Replacement Therapy | 8.8 |
| Placebo | 7.3 |
Inducible myocardial ischemia measured by P-31 gated magnetic resonance cardiac spectroscopy (MRS) is reported as change (∆) in PCr/ATP ratio, with isometric submaximal handgrip stress. PCr/ATP ratio defined as (stress-[average of rest and recovery periods]) / average of rest and recover periods X 100, and expressed as % mean ± SD. For this trial, myocardial ischemia was pre-specified as a fall in quantitative PCR/ATP ratio >20% from rest, and a lower value is considered indicative of greater ischemia. (NCT00600106)
Timeframe: 12 weeks
| Intervention | percent change in PCR/ATP ratio (Mean) |
|---|---|
| Hormone Replacement Therapy | -7.7 |
| Placebo | 1.1 |
Inducible myocardial ischemia measured by P-31 gated magnetic resonance cardiac spectroscopy (MRS) is reported as change (∆) in PCr/ATP ratio, with isometric submaximal handgrip stress. PCr/ATP ratio defined as (stress-[average of rest and recovery periods]) / average of rest and recover periods X 100, and expressed as % mean ± SD. For this trial, myocardial ischemia was pre-specified as a fall in quantitative PCR/ATP ratio >20% from rest, and a lower value is considered indicative of greater ischemia. (NCT00600106)
Timeframe: Baseline
| Intervention | percent changed in PCR/ATP ratio (Mean) |
|---|---|
| Hormone Replacement Therapy | -13.8 |
| Placebo | -7.0 |
"Physical functional disability measured by exercise stress testing. Functional capacity was measured as metabolism equivalents (METs), exercise duration, and exercise-induced chest pain.~In electrocardiography, the ST segment connects the QRS complex and the T wave and has duration of 80 to 120 ms. It should be essentially level with the PR and TP segment. The normal ST segment has a slight upward concavity. Flat, downsloping, or depressed ST segment may indicate coronary ishcemia. Positive treadmill exercise stress test (>1.0 mm horizontal / downsloping or >1.5 upsloping ST segment depression measured 0.08 msec after the J point)." (NCT00600106)
Timeframe: Baseline
| Intervention | mm (Mean) |
|---|---|
| Hormone Replacement Therapy | -0.79 |
| Placebo | -0.79 |
Physical functional disability measured by exercise stress testing. Functional capacity was measured as metabolism equivalents (METs), exercise duration, and exercise-induced chest pain. (NCT00600106)
Timeframe: Baseline
| Intervention | metabolism equivalents (Mean) |
|---|---|
| Hormone Replacement Therapy | 6.1 |
| Placebo | 5.8 |
Physical functional disability measured by exercise stress testing. Functional capacity was measured as metabolism equivalents (METs), exercise duration, and exercise-induced chest pain. (NCT00600106)
Timeframe: Exit (12 weeks)
| Intervention | metabolism equivalents (Mean) |
|---|---|
| Hormone Replacement Therapy | 6.1 |
| Placebo | 5.4 |
Physical functional disability measured by exercise stress testing. Functional capacity was measured as metabolism equivalents (METs), exercise duration, and exercise-induced chest pain. A MET is defined as the resting metabolic rate, that is, the amount or oxygen consumet at rest, sitting quietly in a chair, approximately 3.5 ml O2 / kg / min (1.2 kcallmin for a 70-kg person). As such, work at METs requires twice the resting metabolism or 7.0 ml O2/kg/min, and so on. (NCT00600106)
Timeframe: Baseline
| Intervention | metabolism equivalents (Mean) |
|---|---|
| Hormone Replacement Therapy | 5.4 |
| Placebo | 5.4 |
Physical functional disability measured by exercise stress testing. Functional capacity was measured as metabolism equivalents (METs), exercise duration, and exercise-induced chest pain. A MET is defined as the resting metabolic rate, that is, the amount or oxygen consumet at rest, sitting quietly in a chair, approximately 3.5 ml O2 / kg / min (1.2 kcallmin for a 70-kg person). As such, work at METs requires twice the resting metabolism or 7.0 ml O2/kg/min, and so on. (NCT00600106)
Timeframe: Exit at 12 weeks
| Intervention | metabolism equivalents (Mean) |
|---|---|
| Hormone Replacement Therapy | 6.1 |
| Placebo | 5.4 |
"Physical functional disability measured by exercise stress testing. Functional capacity was measured as metabolism equivalents (METs), exercise duration, and exercise-induced chest pain.~In electrocardiography, the ST segment connects the QRS complex and the T wave and has duration of 80 to 120 ms. It should be essentially level with the PR and TP segment. The normal ST segment has a slight upward concavity. Flat, downsloping, or depressed ST segment may indicate coronary ishcemia. Positive treadmill exercise stress test (>1.0 mm horizontal / downsloping or >1.5 upsloping ST segment depression measured 0.08 msec after the J point)." (NCT00600106)
Timeframe: Exit (12 weeks)
| Intervention | mm (Mean) |
|---|---|
| Hormone Replacement Therapy | -1.05 |
| Placebo | -0.63 |
"Quality of life assessed by cardiac symptoms and psychological questionnaires (SF 36 scale - Short Form Health Survey) The SF-36 includes one multi-item scale that assesses eight health concepts: 1) limitations in physical activities because of health problems; 2) limitations in social activities because of physical or emotional problems; 3) limitations in usual role activities because of physical health problems; 4) bodily pain; 5) general mental health (psychological distress and well-being); 6) limitations in usual role activities because of emotional problems; 7) vitality (energy and fatigue); and 8) general health perceptions.~Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability." (NCT00600106)
Timeframe: 12 weeks
| Intervention | units on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Physical functioning | Role-physical | Role-emotional | Bodily pain | General health | Mental health | Vitality | Social functioning | |
| Hormone Replacement Therapy | 59.4 | 58.8 | 76.5 | 54.5 | 55.2 | 66.4 | 35.6 | 59.4 |
| Placebo | 44.4 | 25.0 | 66.7 | 41.5 | 57.2 | 69.3 | 41.2 | 56.1 |
"Quality of life assessed by cardiac symptoms and psychological questionnaires (SF 36 scale - Short Form Health Survey) The SF-36 includes one multi-item scale that assesses eight health concepts: 1) limitations in physical activities because of health problems; 2) limitations in social activities because of physical or emotional problems; 3) limitations in usual role activities because of physical health problems; 4) bodily pain; 5) general mental health (psychological distress and well-being); 6) limitations in usual role activities because of emotional problems; 7) vitality (energy and fatigue); and 8) general health perceptions.~Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability." (NCT00600106)
Timeframe: Baseline
| Intervention | units on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Physical functioning | Role-physical | Role-emotional | Bodily pain | General health | Mental health | Vitality | Social functioning | |
| Hormone Replacement Therapy | 60.8 | 54.2 | 70.3 | 53.3 | 55.4 | 66.7 | 35.6 | 59.4 |
| Placebo | 43.8 | 37.3 | 66.7 | 42.1 | 57.4 | 65.7 | 42.9 | 53.2 |
Quality of life assessed by menopausal symptoms and psychological questionnaires (NCT00600106)
Timeframe: 12 weeks
| Intervention | percent of participants (Number) | ||||
|---|---|---|---|---|---|
| Hot flushes or flashing | Poor memory | Change in sexual desire | Vaginal dryness | Avoiding intimacy | |
| Hormone Replacement Therapy | 41 | 59 | 35 | 35 | 24 |
| Placebo | 89 | 78 | 67 | 67 | 56 |
Quality of life assessed by menopausal symptoms and psychological questionnaires (NCT00600106)
Timeframe: Baseline
| Intervention | percent of participants (Number) | ||||
|---|---|---|---|---|---|
| Hot flushes or flashing | Poor memory | Change in sexual desire | Vaginal dryness | Avoiding intimacy | |
| Hormone Replacement Therapy | 89 | 76 | 50 | 44 | 39 |
| Placebo | 68 | 53 | 37 | 58 | 37 |
6 reviews available for clonidine and Coronary Disease
| Article | Year |
|---|---|
Hypertensive crisis.
Topics: Antihypertensive Agents; Brain Diseases; Cerebrovascular Disorders; Clonidine; Coronary Disease; Dia | 1984 |
[Preoperative evaluation of patients with heart dysfunction and preanesthetic medication].
Topics: Adrenergic alpha-Agonists; Anesthesia, General; Clonidine; Coronary Disease; Heart Failure; Heart Fu | 1996 |
[Central and peripheral alpha-agonist and antagonist drugs in pharmacology and therapy].
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Blood Pressure; Cardiac Output, Lo | 1989 |
Pharmacology, clinical pharmacology and potential therapeutic uses of the specific bradycardiac agent alinidine.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Animals; Clonidine; Coronary Disease; Drug Evaluation; | 1985 |
[Management of peroperative hypertensive crises].
Topics: Adrenergic beta-Antagonists; Anesthesia, General; Calcium Channel Blockers; Clonidine; Coronary Dise | 1988 |
Hypertensive cardiovascular emergencies.
Topics: Antihypertensive Agents; Brain Diseases; Cerebrovascular Disorders; Clonidine; Coronary Disease; Dia | 1985 |
9 trials available for clonidine and Coronary Disease
| Article | Year |
|---|---|
Oral clonidine reduces myocardial ischemia in patients with coronary artery disease undergoing noncardiac surgery.
Topics: Administration, Oral; Aged; Blood Pressure; Clonidine; Coronary Disease; Double-Blind Method; Electr | 2002 |
Sedative and cardiovascular effects of midazolam and diazepam alone or combined with clonidine in patients undergoing hemodynamic studies for suspected coronary artery disease.
Topics: Adolescent; Adrenergic alpha-Agonists; Adult; Aged; Aged, 80 and over; Analysis of Variance; Blood P | 2007 |
Comparative effects of alinidine and propranolol in ischaemic heart disease.
Topics: Blood Pressure; Clinical Trials as Topic; Clonidine; Coronary Angiography; Coronary Disease; Double- | 1982 |
Effects of clonidine on sinus node function in man.
Topics: Aged; Bradycardia; Clinical Trials as Topic; Clonidine; Coronary Disease; Diabetes Complications; El | 1981 |
Premedication with oral and transdermal clonidine provides safe and efficacious postoperative sympatholysis.
Topics: Administration, Cutaneous; Administration, Oral; Aged; Anesthesia; Clonidine; Coronary Disease; Doub | 1994 |
Imipramine in patients with chest pain despite normal coronary angiograms.
Topics: Adult; Aged; Chest Pain; Chronic Disease; Clonidine; Coronary Angiography; Coronary Disease; Double- | 1994 |
Imipramine in patients with chest pain despite normal coronary angiograms.
Topics: Adult; Aged; Chest Pain; Chronic Disease; Clonidine; Coronary Angiography; Coronary Disease; Double- | 1994 |
Imipramine in patients with chest pain despite normal coronary angiograms.
Topics: Adult; Aged; Chest Pain; Chronic Disease; Clonidine; Coronary Angiography; Coronary Disease; Double- | 1994 |
Imipramine in patients with chest pain despite normal coronary angiograms.
Topics: Adult; Aged; Chest Pain; Chronic Disease; Clonidine; Coronary Angiography; Coronary Disease; Double- | 1994 |
Imipramine in patients with chest pain despite normal coronary angiograms.
Topics: Adult; Aged; Chest Pain; Chronic Disease; Clonidine; Coronary Angiography; Coronary Disease; Double- | 1994 |
Imipramine in patients with chest pain despite normal coronary angiograms.
Topics: Adult; Aged; Chest Pain; Chronic Disease; Clonidine; Coronary Angiography; Coronary Disease; Double- | 1994 |
Imipramine in patients with chest pain despite normal coronary angiograms.
Topics: Adult; Aged; Chest Pain; Chronic Disease; Clonidine; Coronary Angiography; Coronary Disease; Double- | 1994 |
Imipramine in patients with chest pain despite normal coronary angiograms.
Topics: Adult; Aged; Chest Pain; Chronic Disease; Clonidine; Coronary Angiography; Coronary Disease; Double- | 1994 |
Imipramine in patients with chest pain despite normal coronary angiograms.
Topics: Adult; Aged; Chest Pain; Chronic Disease; Clonidine; Coronary Angiography; Coronary Disease; Double- | 1994 |
Small, oral dose of clonidine reduces the incidence of intraoperative myocardial ischemia in patients having vascular surgery.
Topics: Administration, Oral; Adrenergic alpha-Agonists; Adult; Aged; Aged, 80 and over; Blood Pressure; Clo | 1996 |
Effect of sympathoinhibition on exercise performance in patients with heart failure.
Topics: Cardiomyopathy, Dilated; Chronic Disease; Clonidine; Coronary Disease; Exercise; Exercise Test; Hemo | 1997 |
Home blood pressure monitoring: advantages and limitations.
Topics: Blood Pressure Determination; Clonidine; Coronary Disease; Double-Blind Method; Humans; Hypertension | 1991 |
26 other studies available for clonidine and Coronary Disease
| Article | Year |
|---|---|
The impact of a cardioprotective protocol on the incidence of cardiac complications after aortic abdominal surgery.
Topics: Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon, Coronary; Aorta, Abdominal; Clonidine; Coro | 2002 |
Potentials and limitations of angiotensin converting enzyme inhibition in the treatment of hypertension.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Cardiomegaly; Clonidine; | 1984 |
Clonidine: an introduction.
Topics: Antihypertensive Agents; Clonidine; Coronary Disease; Humans; Hypertension; United States | 1980 |
[The hypertensive crisis].
Topics: Acute Disease; Calcium Channel Blockers; Clonidine; Coronary Disease; Diazoxide; Dihydralazine; Dilt | 1984 |
[Hemodynamic actions on alinidine during exercise in patients with coronary artery disease].
Topics: Clonidine; Coronary Disease; Electrocardiography; Hemodynamics; Humans; Male; Middle Aged; Myocardia | 1981 |
Prevention of ischemic ventricular tachycardia of Purkinje origin: role for alpha(2)-adrenoceptors in Purkinje?
Topics: Adrenergic alpha-Agonists; Animals; Blood Pressure; Clonidine; Coronary Disease; Dogs; Electrocardio | 2001 |
Difficult airway management in a patient with severe aortic stenosis, coronary artery disease, and heart failure.
Topics: Aortic Valve Stenosis; Clonidine; Conscious Sedation; Coronary Disease; Heart Failure; Hemodynamics; | 2002 |
The therapeutic value of clonidine in patients with coronary heart disease.
Topics: Angina Pectoris; Arrhythmias, Cardiac; Clonidine; Coronary Disease; Drug Tolerance; Female; Humans; | 1979 |
["Torsades de pointe". Observations on 8 cases].
Topics: Aged; Antihypertensive Agents; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; Clonidine; Coronary | 1979 |
Effects of clonidine on vulnerability to fibrillation in the normal and ischemic canine ventricle.
Topics: Animals; Cisterna Magna; Clonidine; Coronary Disease; Coronary Vessels; Dogs; Electric Stimulation; | 1978 |
Abnormal automatic rhythms in ischemic Purkinje fibers are modulated by a specific alpha 1-adrenergic receptor subtype.
Topics: Adrenergic alpha-Antagonists; Animals; Arrhythmias, Cardiac; Calcium; Clonidine; Coronary Disease; D | 1991 |
Effect of the 'specific bradycardic agent' alinidine on the function of ischemic myocardium.
Topics: Animals; Anti-Arrhythmia Agents; Cardiovascular Agents; Clonidine; Coronary Circulation; Coronary Di | 1991 |
[Alinidine in multi-vessel coronary disease: reduction of stress-induced ischemic reaction].
Topics: Adult; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clonidine; Coronary Disease; Electrocardiograph | 1991 |
Sympathetic mechanisms in poststenotic myocardial ischemia.
Topics: Animals; Carotid Arteries; Clonidine; Coronary Disease; Coronary Vessels; Dogs; Electric Stimulation | 1986 |
Effects of alinidine on metabolic response to high-demand myocardial ischemia.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Cardiovascular Agents; Clonidine; C | 1989 |
Lack of evidence for alpha-adrenergic receptor-mediated mechanisms in the genesis of ischemia in syndrome X.
Topics: Adult; Angina Pectoris; Clonidine; Coronary Angiography; Coronary Disease; Electrocardiography; Exer | 1989 |
Beneficial effects of alpha 2-adrenoceptor activity on ischemic myocardium during coronary hypoperfusion in dogs.
Topics: Acidosis; Adenosine; Animals; Blood Pressure; Clonidine; Coronary Circulation; Coronary Disease; Cyc | 1989 |
Evidence that high affinity (3H)clonidine binding cooperates with H2-receptors in the canine coronary smooth muscle membrane.
Topics: Animals; Cats; Clonidine; Coronary Disease; Coronary Vessels; Cyclic AMP; Muscle, Smooth, Vascular; | 1988 |
[What is safe in the therapy of hypertensive heart disease?].
Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Angiotensin-Converting Enzyme Inhibitors; Animal | 1985 |
[Preoperative oral clonidine improves the cardiovascular stability of hypertensive and coronary patients undergoing surgery].
Topics: Administration, Oral; Cardiovascular System; Clonidine; Coronary Disease; Humans; Hypertension; Prem | 1987 |
Characterization of the inhibitory effect of some antidepressant drugs on the outward transport of norepinephrine in the ischemic myocardium.
Topics: Animals; Antidepressive Agents; Biological Transport, Active; Chromatography, High Pressure Liquid; | 1988 |
Acute haemodynamic effects of a specific bradycardic agent in patients with coronary heart disease and impaired left ventricular function.
Topics: Anti-Arrhythmia Agents; Clonidine; Coronary Disease; Female; Heart Rate; Hemodynamics; Humans; Male; | 1987 |
Effects of specific bradycardic agents on exercise-induced regional myocardial dysfunction in dogs.
Topics: Animals; Anti-Arrhythmia Agents; Benzazepines; Clonidine; Coronary Disease; Depression, Chemical; Do | 1987 |
Antifibrillatory properties of alinidine after coronary artery occlusion in rats.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiovascular Agents; Clonidine; Coronary Di | 1985 |
Anion-channel blockade with alinidine: a specific bradycardic drug for coronary heart disease without negative inotropic activity?
Topics: Adult; Aged; Bradycardia; Cardiac Pacing, Artificial; Cardiotonic Agents; Clonidine; Coronary Diseas | 1985 |
Clonidine in the treatment of severe hypertension.
Topics: Adult; Anesthesia, General; Cerebrovascular Disorders; Clonidine; Coronary Disease; Depression; Huma | 1973 |